Linear IgA bullous dermatosis
Alerts and Notices
SynopsisThis summary discusses adult patients. Linear IgA bullous dermatosis of childhood is addressed separately.
Linear IgA bullous dermatosis (LABD) is a rare immune-mediated disorder that occurs in both children and adults. The disease is defined by the presence of a homogenous deposition of IgA in a linear band at the epidermal-dermal junction. The 3 main types of LABD include the drug-induced, pediatric, and adult forms of the disease.
In the adult form, LABD most commonly presents in the fifth decade of life. Clinical presentation is highly variable, ranging from urticarial plaques, papules, and papulovesicles to large erosions, and the rash can be focal or generalized. Mucosal erosions (which can affect any mucosal surface) are common and may be severe and result in scarring. LABD may be associated with ulcerative colitis and, rarely, with hematologic and solid organ malignancies.
The drug-induced LABD variant usually occurs 1-4 weeks after starting the offending medication and resolves within several weeks of stopping the medication. It resembles classic LABD clinically. It can present with more widespread bullous involvement than non-drug-induced disease. Localized or widespread macular erythema may be seen in association. Localized, morbilliform, erythema multiforme-like with targetoid lesions, and Stevens-Johnson-like presentations have also been described. A number of drugs have been associated with LABD, most commonly vancomycin. Other causative agents include a variety of antibiotics (eg, trimethoprim-sulfamethoxazole, amoxicillin), NSAIDs, simvastatin, cyclosporine, furosemide, lithium, captopril, phenytoin, interleukin-2, interferon gamma, and amiodarone. IgA nephropathy can be rarely associated with the cutaneous eruption of drug-induced LABD.
Most patients with LABD (of any type) have IgA1 antibodies to a 97-kDa and a 120-kDa fragment of the extracellular portion of bullous pemphigoid antigen 2 (BP180 / type XVII collagen), typically the 15 collagenous domain and less frequently the NC16A epitope. Reactivity to collagen VII, laminin-332, and laminin gamma-1 have also been described. Collagen VII has been shown to be the antigen target in a small group of patients with vancomycin-induced LABD.
L13.8 – Other specified bullous disorders
95330001 – Linear immunoglobulin A dermatosis dermatosis
Differential Diagnosis & Pitfalls
- Dermatitis herpetiformis (DH) – Clinical lesions of LABD can resemble those of DH, and 5%-10% of DH patients can have linear IgA on DIF; thus, serology is needed to distinguish the two entities. The absence of an associated gluten-sensitive enteropathy confirms LABD.
- Bullous pemphigoid
- Epidermolysis bullosa acquisita-LABD subtype can be difficult to distinguish clinically, but DIF is typically IgG predominant at the basement membrane zone.
- Subcorneal pustular dermatosis (formerly Sneddon-Wilkinson disease)
- Bullous fixed drug eruption has a history of inciting drug and usually presents with a solitary lesion.
- Porphyria cutanea tarda and pseudoporphyria present with bullae, milia, and hypertrichosis in sun-exposed areas.
- Pemphigus vulgaris and pemphigus foliaceus have flaccid (fragile) bullae.
- Insect bite reaction
- Bullae secondary to lymphedema
- Contact dermatitis with bullae
- Poison ivy dermatitis
- Bullous impetigo will have associated honey-colored crust
- Bullous cellulitis
- Leukocytoclastic vasculitis
- Immunoglobulin A vasculitis (formerly Henoch-Schönlein purpura)
- Erythema multiforme (EM) – Particularly drug-induced LABD resembling EM. DIF is helpful in distinguishing.
- Mucous membrane pemphigoid
Drug Reaction DataBelow is a list of drugs with literature evidence indicating an adverse association with this diagnosis. The list is continually updated through ongoing research and new medication approvals. Click on Citations to sort by number of citations or click on Medication to sort the medications alphabetically.
Linear IgA bullous dermatosis